Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first therapy for severe equine asthma
Horses with severe equine asthma struggle to breath, even at rest. Last week, the European Commission granted marketing authorization1 to Boehringer Ingelheim for the new Aservo® EquiHaler® - and horses that suffer from severe equine asthma can now benefit from this new therapy.
While inhaled therapies for the treatment of asthma are common in human health, the approval of the Aservo® EquiHaler® marks an industry first in equine medicine, as until now, there has been no approved corticosteroid inhalant therapy licensed for use in horses with severe equine asthma.
The Aservo® EquiHaler® represents the culmination of over a decade of collaboration between Boehringer Ingelheim’s human pharma and animal health R&D groups. The Respimat™ inhaler used in human respiratory disease is differentiated by the unique Soft Mist™ Technology, which was integrated into the new Aservo® EquiHaler® , allowing medication to be inhaled, deep into the lung. “The inhaler is a prime example of leveraging innovation efforts of both our businesses. This has been a strength in the past and we will expand this in the near future to further increase the delivery of innovative solutions for our patients and customers,” shares Eric Haaksma, Head of R&D, Boehringer Ingelheim Animal Health Business Unit.
The newly approved inhaler is designed specifically for use in horses. It includes an ergonomic handle and dosing lever for ease of user handling, and a nostril adaptor that fits gently inside the nostril of the horse, allowing the horses to easily inhale the medicated mist. The active ingredient in the Aservo® EquiHaler® is the prodrug ciclesonide, which is a corticosteroid that is activated directly in the lung, reducing lower airway inflammation associated with severe equine asthma.
“Treating severe equine asthma can be challenging for veterinarians and horse owners, who struggle to find safe and effective ways to help horses breath,” says Erich Schoett, Global Business Head of Equine for the Boehringer Ingelheim Animal Health Business Unit. “Bringing a new, safe and effective treatment to the market is something that we can really be proud of. It is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation.”
The Aservo® EquiHaler® is expected to be available for veterinarians in the EU in 2020.
For references and notes to editors, please visit: https://www.boehringer-ingelheim.com/press-release/approval-aservo-equihaler-equine-asthma-therapy
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NY-INTERCELL18.2.2020 06:59:13 CET | Press release
Intercell Empowers Students and Universities to Fuel Education 4.0
HCL-TECHNOLOGIES18.2.2020 05:31:11 CET | Press release
Fonterra Co-operative Selects HCL Technologies for IT Infrastructure Transformation
GSMA17.2.2020 16:02:12 CET | Press release
GSMA Board Statement on MWC Barcelona 2020
ALPEGA-GROUP17.2.2020 16:02:12 CET | Press release
Alpega TMS Shows Impressive Triple-digit Growth in Expanding SME Segment
TX-MARY-KAY-INC.17.2.2020 15:02:06 CET | Press release
Mary Kay Inc. Announces Actress, Philanthropist Monique Coleman as First-Ever Pink Changing Lives Honoree
ABS17.2.2020 14:02:05 CET | Press release
ABS, the Royal Canadian Navy, and Defence Research & Development Canada Launch Digital Asset Framework Pilot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom